<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 05 Apr 2025 04:13:43 +0000</lastbuilddate>
<pubDate>Fri, 04 Apr 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Tirzepatide, HFpEF, and the Kidney: A Triangular Relationship Requiring Measurement of GFR, Not Guesses</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40183720/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 31:S0735-1097(25)05983-2. doi: 10.1016/j.jacc.2025.03.508. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40183720/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40183720</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.508>10.1016/j.jacc.2025.03.508</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40183720</guid>
<pubDate>Fri, 04 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Jozine M Ter Maaten</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2025-04-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Tirzepatide, HFpEF, and the Kidney: A Triangular Relationship Requiring Measurement of GFR, Not Guesses</dc:title>
<dc:identifier>pmid:40183720</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.508</dc:identifier>
</item>
<item>
<title>Genetic and Lifestyle Risks for Coronary Artery Disease and Long-Term Risk of Incident Dementia Subtypes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40181791/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Individuals who are genetically predisposed to developing CAD also face an increased risk of developing dementia in old age. This risk is reduced in those demonstrating healthy lifestyle profiles earlier in the lifespan, particularly in those who may be at an increased risk of developing dementia caused by an underlying vascular pathology.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 4. doi: 10.1161/CIRCULATIONAHA.124.070632. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Shared genetic and lifestyle risk factors may underlie the development of both coronary artery disease (CAD) and dementia. We examined whether an increased genetic risk for CAD is associated with long-term risk of developing all-cause, Alzheimer's, or vascular dementia, and investigated whether differences in potentially modifiable lifestyle factors in the mid- to late-life period may attenuate this risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A prospective cohort study of 365 782 participants free from dementia for at least 5 years after baseline assessment was conducted within the UK Biobank cohort. Genetic risk was assessed using a genomewide polygenic risk score (PRS) for CAD and lifestyle risk using a modified version of the American Heart Association's Life's Essential 8 Lifestyle Risk Score (LRS). Higher values for both scores were deemed to represent increased risk. Primary outcomes were incident all-cause, Alzheimer's, and vascular dementia diagnoses obtained from electronic health records. Secondary outcomes were neuroimaging phenotypes measured in 32 028 participants recalled for magnetic resonance imaging. Sensitivity analyses were conducted to test the extent by which biological and behavioral risk factors contributed to observed associations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 8870 cases of all-cause dementia were observed over a median 13.9-year follow-up. Both genetic (PRS) and lifestyle (LRS) risk scores for CAD were associated with a modestly elevated risk of all-cause dementia (subhazard ratio per SD increase, 1.10 [1.08, 1.12], <i>P</i>&lt;0.001, for PRS and 1.04 [1.02, 1.06], <i>P</i>=0.006, for LRS). This risk appeared largely attributable to underlying vascular dementia diagnoses (subhazard ratio, 1.16 [1.11, 1.21], <i>P</i>&lt;0.001 for PRS and 1.15 [1.09, 1.22], <i>P</i>&lt;0.001, for LRS), because Alzheimer's disease was found to demonstrate moderate associations with PRS alone (subhazard ratio, 1.09 [1.06, 1.13]; <i>P</i>&lt;0.001). LRS was found to have an additive rather than interactive effect with PRS, with individuals in the highest tertiles for both genetic and lifestyle risk for CAD ≈70% more likely to develop vascular dementia during follow-up compared with those in the lowest tertiles for both (subhazard ratio, 1.71 [1.39, 2.11]; <i>P</i>&lt;0.001). This was substantially attenuated in those with a low LRS at baseline, however, regardless of underlying genetic risk (40% to 50% reduction for low versus high LRS tertile regardless of PRS tertile; <i>P</i>&lt;0.001 for all). In a subset of individuals recalled for neuroimaging assessments, those in the highest tertiles for genetic and lifestyle risk for CAD demonstrated a ≈25% greater volume of white matter hyperintensities than those in the lowest risk tertiles, but showed little difference in gray matter or hippocampal volumes. Sensitivity analyses identified associations between both biological and behavioral risk scores with white matter hyperintensity burden and vascular dementia, whereas some Alzheimer's dementia associations showed seemingly paradoxical relationships.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Individuals who are genetically predisposed to developing CAD also face an increased risk of developing dementia in old age. This risk is reduced in those demonstrating healthy lifestyle profiles earlier in the lifespan, particularly in those who may be at an increased risk of developing dementia caused by an underlying vascular pathology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40181791/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40181791</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070632>10.1161/CIRCULATIONAHA.124.070632</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40181791</guid>
<pubDate>Fri, 04 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Arisa Sittichokkananon</dc:creator>
<dc:creator>Victoria Garfield</dc:creator>
<dc:creator>Scott T Chiesa</dc:creator>
<dc:date>2025-04-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Genetic and Lifestyle Risks for Coronary Artery Disease and Long-Term Risk of Incident Dementia Subtypes</dc:title>
<dc:identifier>pmid:40181791</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070632</dc:identifier>
</item>
<item>
<title>Piezo1 in PASMCs: Critical for Hypoxia-Induced Pulmonary Hypertension Development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40181773/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study provides evidence that Piezo1 expressed in PASMCs is critically involved in the pathogenesis of PH by controlling pulmonary vascular tone, arterial remodeling, and associated lung capillary rarefaction due to endothelial cell senescence.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 4. doi: 10.1161/CIRCRESAHA.124.325475. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Pulmonary hypertension (PH) is a life-threatening and progressive yet incurable disease. The hallmarks of PH comprise (1) sustained contraction and (2) excessive proliferation of pulmonary arterial smooth muscle cells (PASMCs). A major stimulus to which PASMCs are exposed during PH development is altered mechanical stress, originating from increased blood pressure, changes in blood flow velocity, and a progressive stiffening of pulmonary arteries. Mechanosensitive ion channels, including Piezo1, perceive such mechanical stimuli and translate them into a variety of cellular responses, including contractility or proliferation. Thus, the objective of the present study was to elucidate the specific role of Piezo1 in PASMCs for PH development and progression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The cell-type specific function of Piezo1 in PH was assessed in (1) PASMCs and lung tissues from patients with PH and (2) 2 mouse strains characterized by smooth muscle cell-specific, conditional Piezo1 knockout. Taking advantage of these strains, the smooth muscle cell-specific role of Piezo1 in PH development and progression was assessed in isolated, perfused, and ventilated mouse lungs, wire myography, and proliferation assays. Finally, in vivo function of smooth muscle cell-specific Piezo1 knockout was evaluated upon induction of chronic hypoxia-induced PH in these mice with insights into pulmonary vascular cell senescence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with healthy controls, PASMCs from patients with PH featured an elevated Piezo1 expression and increased proliferative phenotype. Smooth muscle cell-specific Piezo1 deletion, as confirmed via quantitative real-time polymerase chain reaction and patch clamp recordings, prevented the hypoxia-induced increase in PASMC proliferation in mice. Moreover, Piezo1 knockout reduced hypoxic pulmonary vasoconstriction in isolated, perfused, and ventilated mouse lungs, endothelial-denuded pulmonary arteries, and hemodynamic measurements in vivo. Consequently, Piezo1-deficient mice were considerably protected against chronic hypoxia-induced PH development with ameliorated right heart hypertrophy and improved hemodynamic function. In addition, distal pulmonary capillaries were preserved in the Piezo1-knockout mice, associated with a lower number of senescent endothelial cells.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study provides evidence that Piezo1 expressed in PASMCs is critically involved in the pathogenesis of PH by controlling pulmonary vascular tone, arterial remodeling, and associated lung capillary rarefaction due to endothelial cell senescence.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40181773/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40181773</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325475>10.1161/CIRCRESAHA.124.325475</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40181773</guid>
<pubDate>Fri, 04 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Fenja Knoepp</dc:creator>
<dc:creator>Shariq Abid</dc:creator>
<dc:creator>Amal Houssaini</dc:creator>
<dc:creator>Larissa Lipskaia</dc:creator>
<dc:creator>Mira Yasemin Gökyildirim</dc:creator>
<dc:creator>Emmanuelle Born</dc:creator>
<dc:creator>Elisabeth Marcos</dc:creator>
<dc:creator>Malika Arhatte</dc:creator>
<dc:creator>Edyta Glogowska</dc:creator>
<dc:creator>Nora Vienney</dc:creator>
<dc:creator>Andreas Günther</dc:creator>
<dc:creator>Simone Kraut</dc:creator>
<dc:creator>Ingrid Breitenborn-Mueller</dc:creator>
<dc:creator>Karin Quanz</dc:creator>
<dc:creator>Dagmar Fenner-Nau</dc:creator>
<dc:creator>Geneviève Derumeaux</dc:creator>
<dc:creator>Norbert Weissmann</dc:creator>
<dc:creator>Eric Honoré</dc:creator>
<dc:creator>Serge Adnot</dc:creator>
<dc:date>2025-04-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Piezo1 in PASMCs: Critical for Hypoxia-Induced Pulmonary Hypertension Development</dc:title>
<dc:identifier>pmid:40181773</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325475</dc:identifier>
</item>
<item>
<title>PCR London Valves: a pioneering course at the centre of advances in the treatment of heart valve disease for over 15 years</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40181574/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 4:ehaf103. doi: 10.1093/eurheartj/ehaf103. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40181574/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40181574</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf103>10.1093/eurheartj/ehaf103</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40181574</guid>
<pubDate>Fri, 04 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>PCR London Valves Course Directors and Team</dc:creator>
<dc:date>2025-04-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>PCR London Valves: a pioneering course at the centre of advances in the treatment of heart valve disease for over 15 years</dc:title>
<dc:identifier>pmid:40181574</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf103</dc:identifier>
</item>
<item>
<title>Therapeutic potential of allosteric HECT E3 ligase inhibition</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40179885/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>Targeting ubiquitin E3 ligases is therapeutically attractive; however, the absence of an active-site pocket impedes computational approaches for identifying inhibitors. In a large, unbiased biochemical screen, we discover inhibitors that bind a cryptic cavity distant from the catalytic cysteine of the homologous to E6-associated protein C terminus domain (HECT) E3 ligase, SMAD ubiquitin regulatory factor 1 (SMURF1). Structural and biochemical analyses and engineered escape mutants revealed that...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Apr 2:S0092-8674(25)00274-0. doi: 10.1016/j.cell.2025.03.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Targeting ubiquitin E3 ligases is therapeutically attractive; however, the absence of an active-site pocket impedes computational approaches for identifying inhibitors. In a large, unbiased biochemical screen, we discover inhibitors that bind a cryptic cavity distant from the catalytic cysteine of the homologous to E6-associated protein C terminus domain (HECT) E3 ligase, SMAD ubiquitin regulatory factor 1 (SMURF1). Structural and biochemical analyses and engineered escape mutants revealed that these inhibitors restrict an essential catalytic motion by extending an α helix over a conserved glycine hinge. SMURF1 levels are increased in pulmonary arterial hypertension (PAH), a disease caused by mutation of bone morphogenetic protein receptor-2 (BMPR2). We demonstrated that SMURF1 inhibition prevented BMPR2 ubiquitylation, normalized bone morphogenetic protein (BMP) signaling, restored pulmonary vascular cell homeostasis, and reversed pathology in established experimental PAH. Leveraging this deep mechanistic understanding, we undertook an in silico machine-learning-based screen to identify inhibitors of the prototypic HECT E6AP and confirmed glycine-hinge-dependent allosteric activity in vitro. Inhibiting HECTs and other glycine-hinge proteins opens a new druggable space.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40179885/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40179885</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.001>10.1016/j.cell.2025.03.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40179885</guid>
<pubDate>Thu, 03 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Alexander M K Rothman</dc:creator>
<dc:creator>Amir Florentin</dc:creator>
<dc:creator>Florence Zink</dc:creator>
<dc:creator>Catherine Quigley</dc:creator>
<dc:creator>Olivier Bonneau</dc:creator>
<dc:creator>Rene Hemmig</dc:creator>
<dc:creator>Amanda Hachey</dc:creator>
<dc:creator>Tomas Rejtar</dc:creator>
<dc:creator>Maulik Thaker</dc:creator>
<dc:creator>Rishi Jain</dc:creator>
<dc:creator>Shih-Min Huang</dc:creator>
<dc:creator>Daniel Sutton</dc:creator>
<dc:creator>Jan Roger</dc:creator>
<dc:creator>Ji-Hu Zhang</dc:creator>
<dc:creator>Sven Weiler</dc:creator>
<dc:creator>Simona Cotesta</dc:creator>
<dc:creator>Johannes Ottl</dc:creator>
<dc:creator>Salil Srivastava</dc:creator>
<dc:creator>Alina Kordonsky</dc:creator>
<dc:creator>Reut Avishid</dc:creator>
<dc:creator>Elon Yariv</dc:creator>
<dc:creator>Ritu Rathi</dc:creator>
<dc:creator>Oshrit Khvalevsky</dc:creator>
<dc:creator>Thomas Troxler</dc:creator>
<dc:creator>Sarah K Binmahfooz</dc:creator>
<dc:creator>Oded Kleifeld</dc:creator>
<dc:creator>Nicholas W Morrell</dc:creator>
<dc:creator>Marc Humbert</dc:creator>
<dc:creator>Matthew J Thomas</dc:creator>
<dc:creator>Gabor Jarai</dc:creator>
<dc:creator>Rohan E J Beckwith</dc:creator>
<dc:creator>Jennifer S Cobb</dc:creator>
<dc:creator>Nichola Smith</dc:creator>
<dc:creator>Nils Ostermann</dc:creator>
<dc:creator>John Tallarico</dc:creator>
<dc:creator>Duncan Shaw</dc:creator>
<dc:creator>Sabine Guth-Gundel</dc:creator>
<dc:creator>Gali Prag</dc:creator>
<dc:creator>David J Rowlands</dc:creator>
<dc:date>2025-04-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Therapeutic potential of allosteric HECT E3 ligase inhibition</dc:title>
<dc:identifier>pmid:40179885</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.001</dc:identifier>
</item>
<item>
<title>Genetically encoded reporters of actin filament organization in living cells and tissues</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40179884/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>The cytoskeletal protein actin is crucial for cell shape and integrity throughout eukaryotes. Actin filaments perform essential biological functions, including muscle contraction, cell division, and tissue morphogenesis. These diverse activities are achieved through the ability of actin filaments to be arranged into precise architectures. Much progress has been made in defining the proteome of the actin cytoskeleton, but a detailed appreciation of the dynamic organizational state of the actin...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Apr 1:S0092-8674(25)00276-4. doi: 10.1016/j.cell.2025.03.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The cytoskeletal protein actin is crucial for cell shape and integrity throughout eukaryotes. Actin filaments perform essential biological functions, including muscle contraction, cell division, and tissue morphogenesis. These diverse activities are achieved through the ability of actin filaments to be arranged into precise architectures. Much progress has been made in defining the proteome of the actin cytoskeleton, but a detailed appreciation of the dynamic organizational state of the actin filaments themselves has been hindered by available tools. Fluorescence polarization microscopy is uniquely placed for measuring actin filament organization by exploiting the sensitivity of polarized light excitation to the orientation of fluorophores attached to actin filaments. By engineering fusions of five widely used actin localization reporters to fluorescent proteins with constrained mobility, we have succeeded in developing genetically encoded, green- and red-fluorescent-protein-based reporters for non-invasive, quantitative measurements of actin filament organization in living cells and tissues by fluorescence polarization microscopy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40179884/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40179884</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.003>10.1016/j.cell.2025.03.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40179884</guid>
<pubDate>Thu, 03 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Carla Silva Martins</dc:creator>
<dc:creator>François Iv</dc:creator>
<dc:creator>Shashi Kumar Suman</dc:creator>
<dc:creator>Thomas C Panagiotou</dc:creator>
<dc:creator>Clara Sidor</dc:creator>
<dc:creator>María Ruso-López</dc:creator>
<dc:creator>Camille N Plancke</dc:creator>
<dc:creator>Shizue Omi</dc:creator>
<dc:creator>Rebecca Pagès</dc:creator>
<dc:creator>Maxime Gomes</dc:creator>
<dc:creator>Alexander Llewellyn</dc:creator>
<dc:creator>Sourish Reddy Bandi</dc:creator>
<dc:creator>Laurie Ramond</dc:creator>
<dc:creator>Federica Arbizzani</dc:creator>
<dc:creator>Caio Vaz Rimoli</dc:creator>
<dc:creator>Frank Schnorrer</dc:creator>
<dc:creator>François Robin</dc:creator>
<dc:creator>Andrew Wilde</dc:creator>
<dc:creator>Loïc LeGoff</dc:creator>
<dc:creator>Jean-Denis Pedelacq</dc:creator>
<dc:creator>Antoine Jégou</dc:creator>
<dc:creator>Stéphanie Cabantous</dc:creator>
<dc:creator>Sergio A Rincon</dc:creator>
<dc:creator>Cristel Chandre</dc:creator>
<dc:creator>Sophie Brasselet</dc:creator>
<dc:creator>Manos Mavrakis</dc:creator>
<dc:date>2025-04-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Genetically encoded reporters of actin filament organization in living cells and tissues</dc:title>
<dc:identifier>pmid:40179884</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.003</dc:identifier>
</item>
<item>
<title>A chemical radar allows bacteria to detect and kill predators</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40179883/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>Amoebal predation exerts a strong evolutionary selection pressure on bacteria, thus driving the development of effective predator-defense strategies. However, little is known about the molecular interplay between bacteria and predators, particularly how bacteria can sense and kill their microbial predators. We show how the ubiquitous bacterium Pseudomonas syringae detects and kills the social amoeba Polysphondylium pallidum. Combining comparative genomics, molecular biology, and chemical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Apr 1:S0092-8674(25)00269-7. doi: 10.1016/j.cell.2025.02.033. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Amoebal predation exerts a strong evolutionary selection pressure on bacteria, thus driving the development of effective predator-defense strategies. However, little is known about the molecular interplay between bacteria and predators, particularly how bacteria can sense and kill their microbial predators. We show how the ubiquitous bacterium Pseudomonas syringae detects and kills the social amoeba Polysphondylium pallidum. Combining comparative genomics, molecular biology, and chemical analyses, we identified a chemical radar system. The system relies on P. syringae secreting the lipopeptide syringafactin, which is deacylated by the amoeba. The resulting peptides are sensed via the bacterial sensor protein chemical radar regulator (CraR) that activates genes for converting the predator-derived signal into the amoebicide pyrofactin. This system is widespread in P. syringae and enables bacteria to infect A. thaliana in the presence of amoebae. Our study advances the understanding of microbial sensing and opens new avenues for the discovery of natural products.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40179883/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40179883</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.033>10.1016/j.cell.2025.02.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40179883</guid>
<pubDate>Thu, 03 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Shuaibing Zhang</dc:creator>
<dc:creator>Kevin Schlabach</dc:creator>
<dc:creator>Victor Hugo Pérez Carrillo</dc:creator>
<dc:creator>Anan Ibrahim</dc:creator>
<dc:creator>Shahran Nayem</dc:creator>
<dc:creator>Anna Komor</dc:creator>
<dc:creator>Ruchira Mukherji</dc:creator>
<dc:creator>Somak Chowdhury</dc:creator>
<dc:creator>Lisa Reimer</dc:creator>
<dc:creator>Felix Trottmann</dc:creator>
<dc:creator>A Corina Vlot</dc:creator>
<dc:creator>Christian Hertweck</dc:creator>
<dc:creator>Ute A Hellmich</dc:creator>
<dc:creator>Pierre Stallforth</dc:creator>
<dc:date>2025-04-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A chemical radar allows bacteria to detect and kill predators</dc:title>
<dc:identifier>pmid:40179883</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.033</dc:identifier>
</item>
<item>
<title>Cell membranes sustain phospholipid imbalance via cholesterol asymmetry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40179882/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>Membranes are molecular interfaces that compartmentalize cells to control the flow of nutrients and information. These functions are facilitated by diverse collections of lipids, nearly all of which are distributed asymmetrically between the two bilayer leaflets. Most models of biomembrane structure and function include the implicit assumption that these leaflets have similar abundances of phospholipids. Here, we show that this assumption is generally invalid and investigate the consequences of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 26:S0092-8674(25)00270-3. doi: 10.1016/j.cell.2025.02.034. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Membranes are molecular interfaces that compartmentalize cells to control the flow of nutrients and information. These functions are facilitated by diverse collections of lipids, nearly all of which are distributed asymmetrically between the two bilayer leaflets. Most models of biomembrane structure and function include the implicit assumption that these leaflets have similar abundances of phospholipids. Here, we show that this assumption is generally invalid and investigate the consequences of lipid abundance imbalances in mammalian plasma membranes (PMs). Using lipidomics, we report that cytoplasmic leaflets of human erythrocyte membranes have >;50% overabundance of phospholipids compared with exoplasmic leaflets. This imbalance is enabled by an asymmetric interleaflet distribution of cholesterol, which regulates cellular cholesterol homeostasis. These features produce unique functional characteristics, including low PM permeability and resting tension in the cytoplasmic leaflet that regulates protein localization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40179882/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40179882</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.034>10.1016/j.cell.2025.02.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40179882</guid>
<pubDate>Thu, 03 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Milka Doktorova</dc:creator>
<dc:creator>Jessica L Symons</dc:creator>
<dc:creator>Xiaoxuan Zhang</dc:creator>
<dc:creator>Hong-Yin Wang</dc:creator>
<dc:creator>Jan Schlegel</dc:creator>
<dc:creator>Joseph H Lorent</dc:creator>
<dc:creator>Frederick A Heberle</dc:creator>
<dc:creator>Erdinc Sezgin</dc:creator>
<dc:creator>Edward Lyman</dc:creator>
<dc:creator>Kandice R Levental</dc:creator>
<dc:creator>Ilya Levental</dc:creator>
<dc:date>2025-04-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Cell membranes sustain phospholipid imbalance via cholesterol asymmetry</dc:title>
<dc:identifier>pmid:40179882</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.034</dc:identifier>
</item>
<item>
<title>Engineering sonogenetic EchoBack-CAR T cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40179881/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>Chimeric antigen receptor (CAR) T cell therapy for solid tumors encounters challenges such as on-target off-tumor toxicity, exhaustion, and limited T cell persistence. Here, we engineer sonogenetic EchoBack-CAR T cells using an ultrasensitive heat-shock promoter screened from a library and integrated with a positive feedback loop from CAR signaling, enabling long-lasting CAR expression upon focused-ultrasound (FUS) stimulation. EchoBack-hGD2CAR T cells, targeting disialoganglioside GD2,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 23:S0092-8674(25)00271-5. doi: 10.1016/j.cell.2025.02.035. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Chimeric antigen receptor (CAR) T cell therapy for solid tumors encounters challenges such as on-target off-tumor toxicity, exhaustion, and limited T cell persistence. Here, we engineer sonogenetic EchoBack-CAR T cells using an ultrasensitive heat-shock promoter screened from a library and integrated with a positive feedback loop from CAR signaling, enabling long-lasting CAR expression upon focused-ultrasound (FUS) stimulation. EchoBack-hGD2CAR T cells, targeting disialoganglioside GD2, exhibited potent cytotoxicity and persistence in 3D glioblastoma (GBM) models. In mice, EchoBack-hGD2CAR T cells suppressed GBM without off-tumor toxicity and outperformed their constitutive counterparts. Single-cell RNA sequencing revealed enhanced cytotoxicity and reduced exhaustion in EchoBack-CAR T cells compared with the standard CAR T cells. This EchoBack design was further adapted to target prostate-specific membrane antigen (EchoBack-PSMACAR) for prostate cancer treatment, demonstrating long-lasting tumor suppression with minimal off-tumor toxicity. Thus, the sonogenetic EchoBack-CAR T cells can serve as a versatile, efficient, and safe strategy for solid tumor treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40179881/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40179881</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.035>10.1016/j.cell.2025.02.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40179881</guid>
<pubDate>Thu, 03 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Longwei Liu</dc:creator>
<dc:creator>Peixiang He</dc:creator>
<dc:creator>Yuxuan Wang</dc:creator>
<dc:creator>Fengyi Ma</dc:creator>
<dc:creator>Dulei Li</dc:creator>
<dc:creator>Zhiliang Bai</dc:creator>
<dc:creator>Yunjia Qu</dc:creator>
<dc:creator>Linshan Zhu</dc:creator>
<dc:creator>Chi Woo Yoon</dc:creator>
<dc:creator>Xi Yu</dc:creator>
<dc:creator>Yixuan Huang</dc:creator>
<dc:creator>Zhengyu Liang</dc:creator>
<dc:creator>Yiming Zhang</dc:creator>
<dc:creator>Kunshu Liu</dc:creator>
<dc:creator>Tianze Guo</dc:creator>
<dc:creator>Yushun Zeng</dc:creator>
<dc:creator>Qifa Zhou</dc:creator>
<dc:creator>H Kay Chung</dc:creator>
<dc:creator>Rong Fan</dc:creator>
<dc:creator>Yingxiao Wang</dc:creator>
<dc:date>2025-04-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Engineering sonogenetic EchoBack-CAR T cells</dc:title>
<dc:identifier>pmid:40179881</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.035</dc:identifier>
</item>
<item>
<title>Outcomes of Transcatheter Aortic Valve Replacement in Low-Risk Patients in the United States: A Report From the STS/ACC TVT Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40177743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: One-year outcomes among real-world trial-eligible patients are excellent, but adverse events are higher compared with published clinical trial data, likely because of greater comorbidity burden and lower baseline Kansas City Cardiomyopathy Questionnaire score. These data can help inform expected outcomes and health status after low-risk TAVR.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 3. doi: 10.1161/CIRCULATIONAHA.124.071838. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of measuring the quality of clinical technology adoption.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We identified heart team-designated low-risk patients undergoing TAVR for trileaflet severe, symptomatic aortic stenosis in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Registry, as well as a subset of patients who met low-risk trial inclusion and exclusion criteria, from January 2020 to March 2024. Outcomes (mortality, stroke, new pacemaker, and "alive and well," defined as alive at 1 year with Kansas City Cardiomyopathy Questionnaire score ≥60 and ≤10-point decrease from baseline) at 30 days and 1 year were assessed. Multivariable models were developed to assess predictors of death within 1 year after TAVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 383 030 patients who underwent TAVR during the study period, 108 407 (28%) were designated low risk by the heart team, and 68 194 (18%) met other study inclusion and exclusion criteria. Of these, 62% (n=42 093) would have been eligible for the low-risk trials. In the overall heart team-designated low-risk population, 30-day outcomes included 0.8% mortality, 1.5% stroke, and 8.4% new permanent pacemaker requirement; 1-year outcomes included 4.6% mortality, 2.6% stroke, and 90% alive and well. In the trial-eligible population, 0.6% mortality, 1.4% stroke, and 8.0% new permanent pacemaker requirement had occurred by 30 days; values at 1 year included 3.1% mortality, 2.4% stroke, and 92% alive and well. Notable multivariable predictors of 1-year mortality were atrial fibrillation, nontransfemoral access, and lower baseline Kansas City Cardiomyopathy Questionnaire score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: One-year outcomes among real-world trial-eligible patients are excellent, but adverse events are higher compared with published clinical trial data, likely because of greater comorbidity burden and lower baseline Kansas City Cardiomyopathy Questionnaire score. These data can help inform expected outcomes and health status after low-risk TAVR.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40177743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40177743</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071838>10.1161/CIRCULATIONAHA.124.071838</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40177743</guid>
<pubDate>Thu, 03 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Andrew M Vekstein</dc:creator>
<dc:creator>Zachary K Wegermann</dc:creator>
<dc:creator>Pratik Manandhar</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>G Chad Hughes</dc:creator>
<dc:creator>J Kevin Harrison</dc:creator>
<dc:creator>Tsuyoshi Kaneko</dc:creator>
<dc:creator>Samir R Kapadia</dc:creator>
<dc:creator>Konstantinos Stathogiannis</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Suzanne Arnold</dc:creator>
<dc:creator>Andrzej S Kosinski</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Wayne B Batchelor</dc:creator>
<dc:creator>Vinod H Thourani</dc:creator>
<dc:creator>Sreekanth Vemulapalli</dc:creator>
<dc:date>2025-04-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Outcomes of Transcatheter Aortic Valve Replacement in Low-Risk Patients in the United States: A Report From the STS/ACC TVT Registry</dc:title>
<dc:identifier>pmid:40177743</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071838</dc:identifier>
</item>
<item>
<title>Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175709/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>Clonal haematopoiesis is the clonal expansion of blood stem cells with acquired mutations. Clonal haematopoiesis of indeterminate potential (CHIP), traditionally defined as clonal haematopoiesis driven by a pre-leukaemic mutation in at least 2% of sequenced alleles, affects 10-20% of individuals aged >;70 years. Although CHIP is considered a precursor condition for haematological malignancies, population-based data suggest that the majority of CHIP-associated mortality is attributable to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Apr 2. doi: 10.1038/s41569-025-01148-9. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Clonal haematopoiesis is the clonal expansion of blood stem cells with acquired mutations. Clonal haematopoiesis of indeterminate potential (CHIP), traditionally defined as clonal haematopoiesis driven by a pre-leukaemic mutation in at least 2% of sequenced alleles, affects 10-20% of individuals aged >;70 years. Although CHIP is considered a precursor condition for haematological malignancies, population-based data suggest that the majority of CHIP-associated mortality is attributable to non-malignant conditions, such as cardiovascular disease. Observational human studies have shown that CHIP is a strong and independent predictor of the onset and progression of atherosclerotic cardiovascular disease, heart failure and arrhythmia. In addition, findings from animal experiments suggest that CHIP is causally involved in these diseases and might be a risk factor that can be targeted with therapeutics. As our understanding of the cardiovascular implications of CHIP and other types of clonal haematopoiesis rapidly expands, it has become increasingly clear that clonal haematopoiesis subtypes have substantial heterogeneity with respect to magnitude of effect and underlying mechanisms for different cardiovascular diseases. In this Review, we discuss clonal haematopoiesis as a prognostic factor for numerous cardiovascular diseases, highlight its potential as a therapeutic target and propose a potential role for CHIP in cardiovascular precision medicine.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175709/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40175709</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01148-9>10.1038/s41569-025-01148-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175709</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Art Schuermans</dc:creator>
<dc:creator>Michael C Honigberg</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target</dc:title>
<dc:identifier>pmid:40175709</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01148-9</dc:identifier>
</item>
<item>
<title>Tunnelling nanotube-like structures facilitate cell-cell communication during heart development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175708/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Apr 2. doi: 10.1038/s41569-025-01151-0. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175708/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40175708</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01151-0>10.1038/s41569-025-01151-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175708</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Tunnelling nanotube-like structures facilitate cell-cell communication during heart development</dc:title>
<dc:identifier>pmid:40175708</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01151-0</dc:identifier>
</item>
<item>
<title>Reply: Optimizing Care During the "Golden Day of Shock"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175023/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1469. doi: 10.1016/j.jacc.2025.01.031.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175023/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40175023</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.031>10.1016/j.jacc.2025.01.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175023</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Van-Khue Ton</dc:creator>
<dc:creator>Song Li</dc:creator>
<dc:creator>Navin K Kapur</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Optimizing Care During the "Golden Day of Shock"</dc:title>
<dc:identifier>pmid:40175023</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.031</dc:identifier>
</item>
<item>
<title>Challenges in Applying the CSWG-SCAI Shock Classification: Insights and Considerations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1467-1468. doi: 10.1016/j.jacc.2024.09.1250.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40175022</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1250>10.1016/j.jacc.2024.09.1250</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175022</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Guglielmo Gallone</dc:creator>
<dc:creator>Jorge A Ortega-Hernandez</dc:creator>
<dc:creator>Pier Paolo Bocchino</dc:creator>
<dc:creator>Luca Baldetti</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Challenges in Applying the CSWG-SCAI Shock Classification: Insights and Considerations</dc:title>
<dc:identifier>pmid:40175022</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1250</dc:identifier>
</item>
<item>
<title>Serial Shock Severity Assessment Investigation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1466. doi: 10.1016/j.jacc.2024.09.1249.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40175021</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1249>10.1016/j.jacc.2024.09.1249</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175021</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Harry B Peled</dc:creator>
<dc:creator>Nhu Quyen Dau</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Serial Shock Severity Assessment Investigation</dc:title>
<dc:identifier>pmid:40175021</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1249</dc:identifier>
</item>
<item>
<title>Reply: The Drug-Coated Balloon-Bifurcation Trial (DCB-BIF): A Flash in the Pan?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1465. doi: 10.1016/j.jacc.2025.01.032.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40175020</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.032>10.1016/j.jacc.2025.01.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175020</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Xiaofei Gao</dc:creator>
<dc:creator>Shao-Liang Chen</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: The Drug-Coated Balloon-Bifurcation Trial (DCB-BIF): A Flash in the Pan?</dc:title>
<dc:identifier>pmid:40175020</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.032</dc:identifier>
</item>
<item>
<title>The Drug-Coated Balloon-Bifurcation Trial (DCB-BIF): A Flash in the Pan?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175019/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1464. doi: 10.1016/j.jacc.2024.12.034.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175019/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40175019</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.034>10.1016/j.jacc.2024.12.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175019</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Leontin Lazar</dc:creator>
<dc:creator>Bharat Khialani</dc:creator>
<dc:creator>Bernardo Cortese</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Drug-Coated Balloon-Bifurcation Trial (DCB-BIF): A Flash in the Pan?</dc:title>
<dc:identifier>pmid:40175019</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.034</dc:identifier>
</item>
<item>
<title>FDA's Proposed Nicotine Regulations: A New Frontier for Cardiovascular Health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175018/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1459-1461. doi: 10.1016/j.jacc.2025.02.022.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175018/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40175018</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.022>10.1016/j.jacc.2025.02.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175018</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Kushal T Kadakia</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>FDA's Proposed Nicotine Regulations: A New Frontier for Cardiovascular Health</dc:title>
<dc:identifier>pmid:40175018</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.022</dc:identifier>
</item>
<item>
<title>The Cardiovascular Care of the Pediatric Athlete</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175017/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>Sports cardiology broadly encompasses the cardiovascular care of individuals who place a high premium on habitual exercise, sports performance, and/or sports competition. Some of the essential aspects within sports cardiology include the preparticipation cardiac evaluation and the management of cardiac diseases in athletes. Although most sports cardiology practitioners are trained in adult cardiology, a significant number of individuals who participate in sports are pediatric-aged, &lt;18 years...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1434-1454. doi: 10.1016/j.jacc.2025.02.010.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Sports cardiology broadly encompasses the cardiovascular care of individuals who place a high premium on habitual exercise, sports performance, and/or sports competition. Some of the essential aspects within sports cardiology include the preparticipation cardiac evaluation and the management of cardiac diseases in athletes. Although most sports cardiology practitioners are trained in adult cardiology, a significant number of individuals who participate in sports are pediatric-aged, &lt;18 years old. Up to two-thirds of children in middle and high school participate in organized sports or are involved in nonorganized recreational sports. The cardiovascular care of pediatric-aged athletes can be challenging because many of the classic tenets and principles in adult sports cardiology do not fully generalize to pediatrics, and there is a lack of the evidence base that may be present for adult athletes. The epidemiology, presentation, and progression of cardiovascular diseases can be significantly different between pediatric and adult athletes. The evaluation of potential diseases and management considerations may also differ between pediatric and adult athletes. Similar to adults, there are "gray zones" where it is difficult to differentiate between normal exercise-induced cardiac remodeling and true cardiac pathology, but the additional lack of normative standards further complicates assessments in pediatric athletes. Management decisions for pediatric athletes are generally based on limited data but carry substantial short- and long-term implications. Thus, shared decision-making as part of the determination of clinical management strategies and for sports participation is critical and requires the participation of the parents or guardian(s). In this state-of-the-art review, key differences between pediatric and adult-aged athletes are highlighted. Specifically, how to define the "pediatric athlete," consider cardiovascular adaptations observed among pediatric athletes, determine preparticipation screening options and optimal symptom-driven evaluations in children, and consider best practices for pediatric athletes with several key cardiac conditions are detailed. The purpose of this document is to represent the first primary reference available to providers who care for pediatric athletes with cardiovascular concerns.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175017/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40175017</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.010>10.1016/j.jacc.2025.02.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175017</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Peter N Dean</dc:creator>
<dc:creator>Julie A Brothers</dc:creator>
<dc:creator>Kristin Burns</dc:creator>
<dc:creator>Jonathan B Edelson</dc:creator>
<dc:creator>Susan Etheridge</dc:creator>
<dc:creator>Dermot M Phelan</dc:creator>
<dc:creator>Keri Shafer</dc:creator>
<dc:creator>Chris Snyder</dc:creator>
<dc:creator>Silvana Molossi</dc:creator>
<dc:creator>Alfred Danielian</dc:creator>
<dc:creator>Eli M Friedman</dc:creator>
<dc:creator>Jeff Hsu</dc:creator>
<dc:creator>Mustafa Husaini</dc:creator>
<dc:creator>Eugene H Chung</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:creator>Jonathan H Kim</dc:creator>
<dc:creator>American College of Cardiology Sports &amp; Exercise Cardiology Council</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Cardiovascular Care of the Pediatric Athlete</dc:title>
<dc:identifier>pmid:40175017</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.010</dc:identifier>
</item>
<item>
<title>Bioprosthetic Aortic Valve Durability and Performance: Implications for Lifetime Management of Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1431-1433. doi: 10.1016/j.jacc.2025.02.029. Epub 2025 Mar 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40175016</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.029>10.1016/j.jacc.2025.02.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175016</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Samir R Kapadia</dc:creator>
<dc:creator>Grant W Reed</dc:creator>
<dc:creator>Rishi Puri</dc:creator>
<dc:creator>James Yun</dc:creator>
<dc:creator>Amar Krishnaswamy</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bioprosthetic Aortic Valve Durability and Performance: Implications for Lifetime Management of Aortic Stenosis</dc:title>
<dc:identifier>pmid:40175016</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.029</dc:identifier>
</item>
<item>
<title>Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40175015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250405001342&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Five-year valve performance was significantly better after CoreValve/Evolut TAVR compared with surgery. Development of BVD in TAVR and surgery patients was associated with worsened 5-year clinical outcomes. (Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement, NCT01240902; Safety and Efficacy Study of the Medtronic CoreValve System in the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 8;85(13):1419-1430. doi: 10.1016/j.jacc.2025.02.009. Epub 2025 Mar 9.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The incidence and clinical importance of bioprosthetic valve dysfunction (BVD) in patients undergoing supra-annular, self-expanding transcatheter aortic valve replacement (TAVR) or surgery is not well understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to evaluate the 5-year incidence and clinical outcomes of BVD in patients undergoing CoreValve/Evolut TAVR or surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This post hoc analysis pooled data from the U.S. High Risk Pivotal (n = 726) and SURTAVI (n = 1,618) randomized controlled trials (RCTs), the Extreme Risk Pivotal trial (n = 608), and CoreValve Continued Access Study (n = 2,654). The primary endpoint was the incidence of BVD through 5 years from the RCTs. The association of BVD with 5-year clinical outcomes was evaluated in the pooled RCT and non-RCT populations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 5,606 patients evaluated, 3,070 (54.8%) were men, and the mean age was 82.2 ± 7.4 years. A total of 2,344 RCT patients, including 1,227 who received TAVR and 1,117 who received surgery, and 3,262 non-RCT TAVR patients were included. The rate of BVD was lower in RCT patients undergoing CoreValve/Evolut TAVR compared with surgery (9.7% vs 15.3%; subdistribution HR: 0.57; 95% CI: 0.45-0.73; P &lt; 0.001). In the pooled RCT and non-RCT cohort, BVD was associated with increased 5-year all-cause mortality (HR: 1.49; 95% CI: 1.32-1.68; P &lt; 0.001), cardiovascular mortality (HR: 1.76; 95% CI: 1.52-2.03; P &lt; 0.001), and hospitalization for valve disease or worsening heart failure (HR: 1.48; 95% CI: 1.23-1.78; P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Five-year valve performance was significantly better after CoreValve/Evolut TAVR compared with surgery. Development of BVD in TAVR and surgery patients was associated with worsened 5-year clinical outcomes. (Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement, NCT01240902; Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement [SURTAVI], NCT01586910; Safety and Efficacy Continued Access Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement, NCT01531374).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40175015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250405001342&v=2.18.0.post9+e462414">40175015</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.009>10.1016/j.jacc.2025.02.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40175015</guid>
<pubDate>Wed, 02 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Steven J Yakubov</dc:creator>
<dc:creator>Nicolas M Van Mieghem</dc:creator>
<dc:creator>Jae K Oh</dc:creator>
<dc:creator>Saki Ito</dc:creator>
<dc:creator>Kendra J Grubb</dc:creator>
<dc:creator>Daniel O'Hair</dc:creator>
<dc:creator>John K Forrest</dc:creator>
<dc:creator>Hemal Gada</dc:creator>
<dc:creator>Mubashir Mumtaz</dc:creator>
<dc:creator>G Michael Deeb</dc:creator>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Joshua D Rovin</dc:creator>
<dc:creator>Renuka Jain</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Kimberly A Skelding</dc:creator>
<dc:creator>Neal S Kleiman</dc:creator>
<dc:creator>Stanley J Chetcuti</dc:creator>
<dc:creator>Alexandra Dedrick</dc:creator>
<dc:creator>Sarah Verdoliva Boatman</dc:creator>
<dc:creator>Jeffrey J Popma</dc:creator>
<dc:creator>Michael J Reardon</dc:creator>
<dc:date>2025-04-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk</dc:title>
<dc:identifier>pmid:40175015</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.009</dc:identifier>
</item>





























</channel>
</rss>